Amphastar Pharmaceuticals, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Amphastar Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2019-03-31 was $18.97M.
- Amphastar Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2014-12-31 was $0.00.
- Amphastar Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2014-09-30 was $0.00.
- Amphastar Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2021 was -$68.72M.
- Amphastar Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2020 was -$106.00K, a 100.56% decline from fiscal 2019.
- Amphastar Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2019 was $18.97M, a 50.14% decline from fiscal 2018.
- Amphastar Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2018 was $38.04M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2021-12-31 | -$68.72M 10-K · filed 2024-02-29 | |
| 2020-12-31 | -$106.00K 10-K · filed 2023-03-01 | |
| 2019-12-31 | $18.97M 10-K · filed 2022-03-11 | |
| 2019-03-31 | $18.97M 10-Q · filed 2020-11-06 | |
| 2018-12-31 | $38.04M 10-K · filed 2021-03-15 | |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $38.02M 10-K · filed 2017-03-15 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |